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                                                Preface 
 
Introduction 
 
The project titled “Survival of Myeloma Patients on dialysis” was carried out under the 
supervision of Dr Patrick Kelly, a senior Biostatistician of the School of Public Health and with 
the co-supervision of Dr Angela Webster, a Nephrologist and Epidemiologist of the same school. 
The aim of the project was to describe the survival of Myeloma; the second most commonly 
diagnosed blood cancer in Australia. 
  
Student’s role 
My role was to prepare the data for analysis, advising the appropriate analysis, implement the 
agreed analysis plan and interpret the final results.  
The project involved much data manipulation and the majority of my time was spent on this. 
Although I was primarily responsible for analysing the data, I could consult with my supervisor 
and co-supervisor to clarify any statistical issues.  
 
Reflection on learning 
Communication skills:  
I met with my supervisor weekly. During those meetings I explained the work I had conducted 
and presented my results.  We also communicated via email – sending in advance my results and 
summarising our meetings. I also learnt how to write a report after analysing the data. Thus, the 
project enhanced my communication skills both verbally and written, while I was presenting my 
reports and discussed the results on a regular basis with my supervisors. 
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Work patterns/planning: 
The project developed my planning and organisation skills as well. To implement the project, I 
met with my supervisor in regular meetings, contacted through email, sent summaries of analysis 
via email and so on. Also, I maintained a project diary that included the meeting agenda and 
listing of post meeting outcomes. Thus, I was able to integrate the results of the whole project. 
As a result, I learnt how a project is planned and managed within a time frame. I was always 
very prompt in replying to my supervisor’s emails and always attended the meetings on time and 
well prepared. 
 
Statistical principles: 
The project also increased my applied statistical knowledge and skills through hypothesis testing 
and making inference on the test result. More specifically, I had to develop a number of models 
identifying the significant covariates associated with the risk factors of the survival of myeloma 
patients and estimate the risk of death for myeloma patients compared to non-myeloma dialysis 
patients who reached the End Stage Kidney Disease (ESKD) stage.  
 
Statistical issues  
The statistical issues involved the appropriate selection of methods. The proposed methods were 
the survival analysis of the censored data and choosing the correct model including selection of 
appropriate covariates for the model. 
 
Statistical methods: 
The statistical analysis involved methods of applying Kaplan-Meier curves, Cox proportional 
hazard models and Stratified Cox models, which I learnt specifically from ‘Survival Analysis’. 
Also, I applied my learnt knowledge of ‘Categorical Data Analysis’ in order to convert 
continuous variables to categorical variables. I also referred to various statistics books, such as 
Applied Survival Analysis: Regression modelling of time to event data by Hosmer DW. & 
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Lemeshow S. (1999), Survival Analysis: A self-learning text by Kleinbaum DG. & Klein M. 
(1996) and so on. 
 
Statistical computing: 
The work placement project substantially increased my knowledge of statistical computing 
particularly in STATA and some extent SAS, as all analyses and data management were 
conducted in these packages. I also learnt a lot about manipulation and data cleaning. For 
example, each patient had several rows of data and had to be compressed into a single row per 
patient data without losing relevant information for the analyses. I also generated a number of 
new variables, performed cross-tabulations, created various types of graphs and so on. The 
details of these data manipulation process have been explained more elaborately in the ‘data 
manipulation’ area.  
 
Teamwork 
Communication with other team members: 
I had to communicate with other two team members, my supervisor, Dr Patrick Kelly, a senior 
Biostatistician of the School of Public Health and the co-supervisor, Dr Angela Webster, a 
Nephrologist and Epidemiologist of the same school. I met with them on weekly basis and 
sometimes through e-mail regarding progress of my work.  As a result, I developed a sound team 
work skills. 
 
Working within timelines: 
I was able to present the results of the weekly proposed analysis and submitted the portfolio 
within a time frame as instructed by my supervisor. More specifically, I was given set tasks at 
each meeting such as data manipulation, analysis and achieved tasks set for the next meeting. I 
used to use a project diary, where I listed all those activities and maintain the diary accordingly. 
As a result, I have achieved how to work within a time frame. 
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Helping others to understand statistical issues-teaching: 
The project team consists of three members, one of which was an Epidemiologist. Consequently, 
I had to explain the results to her and any statistical issues arose in the meeting particularly the 
models. 
 
Ethical considerations 
I signed the confidentiality agreement while I collected ANZDATA cancer registry data to 
protect privacy of the patients. The signed agreement form is attached in appendix. 
 
Confidentiality issues 
I was strictly undertaken to preserve the confidentiality of the data and not to disclose any 
information of the output. In addition, a copy of the project will be sent to ANZDATA when 
published. 
 
Professional responsibility 
The data were kept password protected to fulfil my undertaken as a professional statistician and 
the communications were limited to the project team members only.  
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Project  
 
Project title 
Survival of Myeloma patients on dialysis 
 
Location and Dates 
School of Public Health, University of Sydney 
July 2008-January 2009 
 
Context 
Dr Angela Webster, the Project Manager and the Chair of the cancer working group of 
ANZDATA was responsible for advising the clinical investigation of the survey data, which are 
updated every after six months. As part of her work, I was given the responsibility of analysing 
the data to investigate the risk factors associated with survival for myeloma patients, who had 
reached end stage kidney disease. 
 
Contribution of student 
As part of my analysis process, I proposed Dr Judy Simpson regarding the details of my analysis 
plan with the consultation of Dr Patrick Kelly that such data can be analysed using Kaplan-Meier 
curves and Cox proportional Hazard models. As a result, I started to meet my supervisors on 
weekly basis to present the results of my progressive work. I carried out all the analysis with the 
consultation of Dr Patrick Kelly and Dr Angela Webster using STATA statistical software. 
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Analysis of End Stage Kidney Disease (ESKD) data using Kaplan-Meier 
survival curves and Cox Proportional Hazard models 
 
1. Project description 
 
End-stage kidney disease (ESKD) or End Stage Renal Disease (ESRD) is a complete or nearly 
complete failure of the kidneys to function to excrete wastes, concentrate urine, and regulate 
electrolytes. End-stage kidney disease occurs usually at the chronic stage. More specifically, 
ESKD occurs when kidney function reach at the point of lower than 10% of its normal function. 
The kidney function is so low at this stage is that a patient without a dialysis or transplantation 
will die from accumulation of fluids and waste products in the body (UMM, 2007). 
 
ANZDATA is the Australian and New Zealand Dialysis and Transplant Registry that collects a 
wide range of statistics which relate to the outcomes of treatment of those with end stage renal 
failure. The ANZDATA is comprised of patients commencing from 1963, the year renal 
replacement therapy was first used in Australia to 2006, who have undergone dialysis and/or a 
kidney transplant for the treatment of ESKD.  The survey data were designed through circulation 
of printed survey forms for each patient at six-month intervals to all dialysis and transplant units 
in Australia and New Zealand. As part of the routine medical care, the kidney specialists collect 
certain information from the people receiving treatment with dialysis or kidney transplantation.  
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1.1 Background, rationale for project 
 
Myeloma, also known as Multiple Myeloma or plasma cell Myeloma, is a cancer of the blood in 
which malignant plasma cells are overproduced in the bone marrow. Myeloma cells typically 
produce excessive amounts of paraprotein or M protein and can cause kidney damage that may 
progress to End Stage Kidney Disease (ESKD). Multiple Myeloma is the second most commonly 
diagnosed blood cancer and around 1200 people are newly diagnosed each year in Australia and 
it will increase as the population ages. Almost 80% of People diagnosed with Myeloma are over 
60 years old and is uncommon in people under 40 years and it also occurs more frequently in 
men than in women. 
 
According to the Australian Institute of Health and Welfare (AIHW), more Australians than ever 
are developing Myeloma and Non-Hodgkin’s lymphoma (NHL). In recently released statistics, 
the AIHW listed the two cancers among the top five cancers. The incidence of Myeloma had 
increased by 44% in the 10 years from 1993 to 2003. A total of 2378 new patients were 
diagnosed for end-stage renal failure in Australia in 2006 (ANZDATA), a rate of 115 per million 
population per year. People who have reached ESKD will require permanent renal replacement 
therapy either by means of dialysis or kidney transplantation to improve their quality of life. The 
standardised incidence ratio of Myeloma cancers (ICD: C90) of Australian ESKD patients on 
dialysis is 9.58(95%CI, 7.64-11.86) (JAMA, 2006). According to the British Medical Journal, 
dialysis is recommended for the treatment of myeloma, as adequate dialysis may improve patient 
tolerance to chemotherapy. It is also reported that the disease may be considered as incurable and 
thus fatal. As a result, renal transplantation for the myeloma patients is discouraged. According 
to the journal named Nephrology Dialysis Transplantation “fear of acceleration of myeloma 
following immunosuppressive therapy directed primarily at T-cells” (NDT, 1996). 
 
 
 
11 
 
1.2 Aim 
 
The project has mainly focussed on the myeloma cancer patients who were treated with dialysis, 
to identify their survival characteristics. The exploratory data analysis has been conducted to 
identify the focussed groups. Cox proportional hazard models were developed for myeloma and 
non-myeloma patients by means of statistical software STATA. 
 
Using data supplied by the Australia and New Zealand Dialysis and Transplant Data Registry 
(ANZDATA), this project will describe the survival of Myeloma patients on dialysis and identify 
the characteristics of improved survival. To identify the variables associated with improved 
survival, the data will be analysed using Kaplan-Meier survival curves, log-rank tests and Cox 
proportional hazards models.  
 
The two main aims of the project were:           
(i) Estimate the risk of death of myeloma patients compared to non-myeloma dialysis patients, 
adjusting for confounding factors. 
(ii) Describe the survival and risk factors of survival for myeloma patients. 
 
2. Data management 
 
Data were supplied from Dr Angela Webster in Stata format, where each row corresponds to a 
cancer for an ESKD patient. If a patient had one row then they had either ‘0’ or ‘1’ cancer. If 
several rows correspond to a patient, then the number of rows is equal to the number of cancers. 
 
The primary data set was comprised of 47935 multiple observations. I had to create a single 
observation file of 45657 patients from multiple observations that is one row per patient. First, 
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data were sorted out the cervix cancers from the Cervical Intraepithelial Neoplasia (CIN), a type 
of cervical pre cancers, which were coded as cancers. The total number of cancers found was 
8453 out of which 212 were cervix cancers. Second, the dataset had two variables for identifying 
the type of cancer a patient had  – “catype”, which coded the different types of cancers a number 
and “typedecr” which was a was a string variable describing the type of cancer in words. I 
checked for any discrepancies between “catype” and “typedescr”- no error was found in the data 
set. Third, we were only interested in dialysis patients because myeloma patients are not eligible 
for a kidney transplant. Hence all transplant patients were removed – this only included one 
myeloma patient, who was diagnosed with myeloma many years after being diagnosed with 
EKSD. Fourth, I sorted the records for each patient- by cancer date by generating sequence 
variable. Fifth, I created new variables such as ‘myeloma’ as cancer type of 10. It was confirmed 
by counting and cross-tabulating myeloma and its sequences that myeloma could not be seen as 
the multiple occurrence of disease for the same patient. Another new variable ‘canceroccureskd’ 
was created from duration of myeloma and ESKD. The details of the new variables and 
categorisation of those variables can be seen in Table-1 in the statistical methods section.  
Finally, the records for each patient were compressed to a single row, but keeping such 
information such the number of total cancers. The details of the steps are summarised by means 
of the following flow chart (Figure 1). Out of the 45657 patients, 664 were patients who had 
myeloma. 
 
 
 
 
 
 
 
 
 
 Figure 1: Flow chart from multiple records per person (1 record per cancer) of all dialysis 
patients in ANZDATA, to single record per patient for those having had at least one myeloma 
where >1 cancer had occurred. 
Excluded; 
First treatment transplant       
 
Observations             1000  
Note: Number of exclusion from 
the cancer type was 105 due to 
exclusion of transplant patients. 
 
Excluded;               
Not true cancer (pre-invasive 
lesions) 
Observations                             51 
Note:  There were 203 observations that 
were not true cancers. Of these 51 
belonged to patients that had one other 
cancer. The remaining observations 
belonged to patients with no other cancer 
and hence the observation is not deleted, 
but edited.  Therefore, 51 observations 
had been dropped due to exclusion of not 
true cancer. 
Excluded; 
Multiple observations removed: 1227
  
 
First treatment dialysis 
 
Observations   46935 
Haemodialysis                                         31998 
Peritoneal dialysis                                  14937 
Total (apparent) cancers                       8348 
 
ANZDATA file; all persons treated for ESRF 
1963-Dec 2006 
Multiple records per person 
Observations   47935 
Persons                     45657 
Total (apparent) cancers    8453 
Cancer and Non-cancer observations 
Observations   46884 
Persons    45657 
Total cancers      8145 
Persons with single cancer                   6918 
Persons with ≥ 2 cancers    1227 
 
Single record per person 
 
Observations   45657 
Total persons   45657 
Non-myeloma dialysis patients 
Total patients: 44,993 Myeloma patients 
Total patients: 664 13 
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I constructed histograms and tables to check the variables such as age, gender, time between 
myeloma and ESKD and so on. See for example, Figure 2, which shows myeloma was very 
uncommon under the age of 40. 
 
Figure 2: Histogram of age at the first treatment of dialysis for myeloma patients. 
0
10
20
30
40
%
 M
ye
lo
m
a 
pa
tie
nt
s
20 40 60 80 100
Age at the 1st treatment(dialysis)
 
 
 
3. Statistical Methods  
 
3.1 Exploratory Data Analysis 
 
Table 1 summarises the characteristics of both myeloma and non-myeloma patients. 
 
15 
 
Table 1: Characteristics of dialysis population with and without myeloma, in Australia and New Zealand, 1963-
2006 
 
 
 
Characteristic Myeloma patients Other patients 
Total (n=664) % (n=44993) % 
Age at ESKD*     
<60  210  31.6 26946 59.9 
60-70  209 31.5 9898 22.0 
>=70  245 36.9 8149 18.1 
Gender     
Female  251 37.8 19186 42.6 
Male 413 62.2 25807 57.4 
Dialysis modality     
haemodialysis  533  80.3 30477         67.7 
Peritoneal dialysis   131  19.7 14516       32.3 
Diagnosis of ESKD     
before 1996 208 31.3 22717  50.5 
1996-2002  214 32.2 12345 27.4 
2002-present  242 36.5 9931    22.1 
Primary renal disease     
Myeloma  488 73.5 4** 0.0 
Possibly myeloma related 54 8.1 928 2.1 
Glomerulonephritis/ IgA nephropathy 44 6.6 14073 31.3 
Other causes 78 11.8 29,988 66.6 
Racial background     
Non-white  40 6.0 9348 20.9 
White  624 94.0 35609 79.1 
16 
 
Other malignancy prior to ESKD     
None 298 
 
44.9 42244 
 
93.9 
Pre-dialysis malignancy 366 55.1 2749 6.1 
Other malignancy subsequent to ESKD     
None  563 84.8 2964 6.6 
Post-dialysis malignancy 101 
 
15.2 42029 93.4 
Other malignancy at same time of ESKD     
None  660 99.4 44984 99.98 
Other malignancy at dialysis 4 0.6 9 0.02 
Status during follow-up     
Alive  126 19.0 18736 41.6 
Died   538  81.0 26257 58.4 
Smoking history at ESKD     
Yes 267 42.2 17133 38.1 
No 397 59.8  27860  61.9 
Diabetes Mellitus                                                                                
Yes 194 29.2 21860 48.6 
No 470 70.8 23133 51.4 
*End Stage Kidney Disease; ** Four non-myeloma patients suffered from Paraproteinaemia those included in Multiple myeloma 
group (Primary renal disease code 17) 
 
We can see from the above table that myeloma is more common in men (62.2%) than in women. 
According to leukaemia foundation, it is found that myeloma is more common in men than in 
women (Leukaemia Foundation, 2006). Again, the result shows that the majority of people 
diagnosed with myeloma are over 60 years old (68.4%). The majority of myeloma patients are 
being treated by haemodialysis (80.3%), the remainder being treated by peritoneal dialysis. The 
report also revealed that most of primary renal diseases, within patients with myeloma, are 
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caused by myeloma (73.5%) disease where 79.4% patients are dying according to censoring 
status. 
 
Figure 3 shows the survival of myeloma and non-myeloma patients. Time is measured from time 
of starting dialysis to death. Censoring occurs if the patient is either alive at last known date or 
else lost to follow-up. The median survival times of myeloma and non-myeloma patients are 1.1 
and 4.5 years respectively.  
 
Figure 3: Survival curves of myeloma and non-myeloma patients 
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3.2 Analysing myeloma patients 
 
The first aim of this project was to identify the risk factors that were associated with survival for 
myeloma patients. This section summarises the analysis that was conducted for this particular 
aim.  
 
The total patients diagnosed with myeloma were 664. Figure 4 shows time from diagnosis of 
myeloma to starting diagnosis. A value of zero indicates those patients who were diagnosed with 
myeloma and starting dialysis at the same time (within 1 month). A value to the left of zero 
indicates those patients who were diagnosed with myeloma before ESKD and a value to the right 
indicates those patients who were diagnosed with myeloma after ESKD. Three hundred and sixty 
nine (369) patients (55.6%) were diagnosed with myeloma prior to starting dialysis, 193 (29.0%) 
of patients were diagnosed with myeloma within one month of starting dialysis and 102 (15.4%) 
of patients were diagnosed with myeloma after starting dialysis. Sixty one (61) patients (9.2%) 
were diagnosed with myeloma within one year of starting dialysis (ESKD) and 41 (6.2%) were 
diagnosed with myeloma more than 1 year after ESKD. 
 
For this project, we wanted to determine the risk factors associated with survival for myeloma 
patients on dialysis. For this reason, it did not seem appropriate to include those patients that 
were on dialysis but did not have myeloma until a substantial time after being on dialysis. In 
consultation with Dr Webster, it was deemed plausible that myeloma may have been the cause of 
ESKD for patients who were diagnosed with myeloma for up to one year after beginning 
dialysis. Therefore, all patients who were diagnosed with myeloma more than one year after 
EKSD were excluded from the survival analysis- 41(6.2%) patients. Thus the results of the 
below analysis are based on 623 patients. 
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Figure 4: Histogram of time (years) between Myeloma and ESKD 
 
 
 
                       Time before                                                                          Time after 
 
 
The survival analysis was with respect to time from ESKD to death. Of the 623, 117 (18.8%) 
were censored. Figure 5 shows the survival curves for potential risk factors of age, sex, treatment 
type, ethnicity, smoking status, diabetes mellitus, cause of primary kidney disease, year of 
diagnosis of ESKD, year of diagnosis of myeloma and duration between myeloma and ESKD. It 
is seen that there is no separation between the different levels for risk factors other than age, 
duration between myeloma and ESKD and primary cause of kidney disease.  
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Figure 5: Kaplan-Meier survival curves of the covariates:  
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a) Probability of survival between different age groups               b) Probability of survival between male and female 
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 c) Probability of survival between haemodialysis and peritoneal dialysis    d) Probability of survival between ethnicity  
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Figure 5 continued 
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 e) Probability of survival between smoker and non-smoker    f) Probability of survival between diabetic and non-diabetic  
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  g) Probability of survival between different groups of primary kidney disease    h) Probability of survival between different   
                                                                                                                                      group of year of diagnosis of ESKD 
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i) Probability of survival between different group of year of diagnosis of myeloma    j) Probability of survival between different                
group of Duration between myeloma and ESKD 
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Cox proportional hazard models were used for the analysis. The Cox model was first fitted singly 
to each variable.  A multivariate model was then developed based on model building strategies 
proposed by Harrell (2006). Variables were entered into the model if the univariate p< 0.25. 
Variables were then dropped if p >0.05, with the exception of gender, which was included in the 
model regardless of statistical significance just to see the difference of hazard ratio between male 
and female. P-values for the Wald test are reported. The results of both the univariate and 
multivariate analysis are given in Table 3. Interaction terms were tested among age, myeloma 
and sex, but none was found to be statistically significant.  
 
From the multivariate model, it can be seen that the only variables associated with survival were 
the age group. More specifically, the risk of dying of myeloma patients is 1.15 times more in 
patients aged 60 to 70 compared to those who are younger than 60 years. The risk of dying of 
myeloma patients is 1.69 times more in patients aged more than 70 compared to those who are 
younger than 60 years. Therefore, the risk of dying is increasing with increasing age. 
 
The risk of dying is 33% lower in the possibly myeloma related disease compared to patients 
with multiple myeloma. The risk of dying is 40% lower in the GN/IgA group compared to 
patients with multiple myeloma. The risk of dying is 36% lower in other diseases group 
compared to patients with multiple myeloma. Therefore, if the patient’s cause of ESKD was not 
diagnosed as myeloma, the risk of dying was lower. 
 
 The model also revealed that the risk of dying is 1.12 times more in male compared to female, 
which is not statistically significant (p=0.23). 
The risk of dying of the patients who got myeloma after one year of ESKD is 0.85 times that of 
the patients who got myeloma at the same time of ESKD. The risk of dying of the patients who 
got myeloma before one year of ESKD is 1.02 times that of the patients who got myeloma at the 
same time of ESKD. The risk of dying of the patients who got myeloma before five year of 
ESKD is 0.74 times that of the patients who got myeloma at the same time of ESKD. The risk of 
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dying of the patients who got myeloma before greater than five years of ESKD is 0.73 times that 
of the patients who got myeloma at the same time of ESKD. Therefore, it was found that the risk 
of dying of the patients who got myeloma after ESKD is more than the patients who got 
myeloma before ESKD. Results seem to suggest that survival is slightly better amongst people 
who are diagnosed with myeloma more than one year before getting ESKD. 
Table 3: Hazard ratios of death of myeloma patients on dialysis 
  Univariate   Multivariate  
Covariates  Hazard 
ratio 
95% CI P-values Hazard 
ratio 
95% CI 
 
 
P-values 
Age    0.001   <0.001 
<60(referent) -   -   
60-70 1.13 (0.91,  1.42)  1.15 (0.92,  1.44)  
>=70 1.51 (1.21,  1.88) 
 
 1.69 (1.35,  2.11)  
Sex   0.33   0.23 
  Female (referent) -   -   
  Male  1.09 (0.91, 1.31) 
 
 1.12 (0.93, 1.34) 
 
 
Primary kidney disease   0.002   0.003 
Multiple myeloma(referent) -   -   
Possibly myeloma related 0.65 (0.47, 0.91)  0.67 (0.47, 0.94)  
GN/IgA 0.62 (0.40, 0.95)  0.60 (0.39, 0.94)  
Other  0.68 (0.50, 0.93) 
 
 0.64 (0.46, 0.88) 
 
 
Duration between myeloma 
and ESKD 
  0.008   0.05 
Myeloma before 1 year of 
ESKD 
1.01 (0.80, 1.27)  1.02 (0.81, 1.29)  
Myeloma before 1 to 5 years 
of ESKD 
0.72 (0.57, 0.92)  0.74 (0.58, 0.95)  
Myeloma before more than 5 
years of ESKD 
0.68 (0.50, 0.94)  0.73 (0.53, 1.01)  
Myeloma at the same time of 
ESKD (referent) 
      
Myeloma after 1 year of  
ESKD  
0.74 (0.54, 1.02)  0.85 (0.61, 1.18)  
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The proportional hazard (PH) assumption was checked for the final model. Stata tests for PH 
using global test. If the global test is not significant (p>0.05), it is assumed that the model 
satisfies the PH assumption. Table 4 shows that the global test was not significant (p=0.52). This 
indicated that the proportional hazard assumption was met. Also, it was found that each covariate 
met the PH assumption. We also looked at the graphical test of PH assumption behind this test 
(Figure 6) to see whether the smoothed lines are horizontal and centred at zero. The plots show 
that all the fitted lines are very flat indicating that the PH assumption was met. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
Table 4: Test of proportional hazards assumption 
 
 
 
Variables      Correlation 
coefficient (Rho) 
Chi-squares Degrees of 
freedom  
P-values 
 
Age group  
    
<60 (referent)     
60-70 0.001   0.63 1 0.43 
>70 -0.007     1.68 1 0.19 
 
Sex     
  Female (referent)     
  Male  0.03 0.45 1 0.50 
 
Primary kidney disease types     
Multiple Myeloma (referent)     
Possibly myeloma related 0.000 0.00 1 0.99 
GN/IgA -0.001 0.00 1 0.99 
Other 0.03 0.50 1 0.48 
 
Duration of Myeloma diagnosis     
Myeloma before 1 year of ESKD 0.01 0.07 1 0.80 
Myeloma before 5 year of ESKD 0.03 0.57 1 0.45 
Myeloma before >5 year of 
ESKD 
-0.06 2.04 1 0.15 
Myeloma at the same time of 
ESKD (referent) 
    
Myeloma after 1 year of ESKD -0.003 0.00 1 0.95 
Global Test  9.12 10 0.52 
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Figure 6: Graphical test of proportional hazard assumption 
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        a) age group 60-70                                b) age group >70 
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     c) PKD (possibly myeloma related)              d) PKD (GN/IgA) 
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          e) PKD (other)                                                                 f) sex (male) 
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The Cox-Snell residual goodness fit to test was used to determine whether the model fits the data 
well (p.225 Hosmer and Lemeshow, 1999). If the model fits the data, we would expect the points 
to lie on the 45 degree line. We can see in Figure 7 that the points follow the 45 degree line very 
closely except for some large values of time, which is not a matter of concern for the censored 
data.  Therefore, we can conclude that the graph shows an overall good of fit to the data.  
 
 
Figure 7: Cox-Snell residual goodness of fit of the model 
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3.2.1 Diabetes 
 
Diabetes status was not collected by ANZDATA until 1990. To check whether diabetes was also 
a risk factor, the data since 1990 were reanalyzed with diabetes status included as a variable in 
the model.  The same model process as before was applied. Table 5 shows the results of this 
model, and it can be seen that the hazard ratios were almost the same as the model using the data 
from all years. The risk of dying of myeloma patients who were diabetic was 0.89 times that of 
the myeloma patients who did not have any diabetes, which was not statistically significant. 
Therefore, it was evident that there exhibited no significant effect of diabetes on survival of 
myeloma patients.  
 
Table 5: Risk of death of myeloma patients since 1990 
 
Covariates Hazard ratio P-values 95% CI   
 
Age  
   
<60 1(referent) - - 
60-70 1.22 0.139 (0.94,  1.60) 
>=70 1.71 0.000 (1.32,  2.21) 
 
Sex    
  Female  1(referent) - - 
  Male  1.15 0.191 (0.93, 1.41) 
 
Primary kidney disease    
Multiple myeloma 1(referent) - - 
Possibly myeloma related 0.63 0.026 (0.42, 0.94) 
GN/IgA 0.51 0.008 (0.31, 0.84) 
Other  0.68 0.035 (0.47, 0.97) 
 
Diabetes     
No 1(referent) - - 
Yes 0.89 0.408 (0.67, 1.18) 
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3.3 Estimating the risk of dying of myeloma vs. non-myeloma patients on dialysis 
 
This section summarises the analysis that was conducted to estimate the risk of dying between 
myeloma compared to non-myeloma patients on dialysis. The reason for comparing myeloma 
and non-myeloma patients was to estimate the risk of dying between myeloma and non-myeloma 
patients with respect to dying once on dialysis, after adjusted for confounding factors. 
 
For the analysis, time was measured from diagnosis of ESKD to death. Figure 8 show that 
myeloma is very uncommon under the age of 40. As a result, the model only included those who 
were 40 years or older so that the non-myeloma and myeloma patients were comparable with 
respect to age. Thus this model has been developed for myeloma and non-myeloma patients, who 
are at least 40 years, as the myeloma is rare under the age of 40 (Leukaemia foundation, 2006). 
Also, I have excluded patients of ESKD before 1990 as the starting year of diagnosis of diabetes 
so that myeloma and non-myeloma patients were comparable with respect to year.  
 
Figure 8: Histogram of age of myeloma and non-myeloma patients 
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Figure 9 show that there is a difference in survival in terms of age group, types of dialysis, 
diabetes, smoking status, year of diagnosis of myeloma and myeloma vs. non-myeloma group, 
while there appears to be no or little difference in terms of gender, ethnicity, year of diagnosis of 
ESKD.  
 
Figure 9: Kaplan-Meier Survival curves of the covariates of myeloma and non-
myeloma patients 
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               a) Probability of survival between different age group                    b) Probability of survival between male and female 
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c) Probability of survival between haemodialysis and peritoneal dialysis     d) Probability of survival between white and non-
white patients. 
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    Figure 9 continued 
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e) Probability of survival between different smoking status   f) Probability of survival between diabetic and non-diabetic 
patients 
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g) Probability of survival between year of diagnosis of ESKD             h) Probability of survival between year of diagnosis of 
Myeloma 
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i) Probability of survival between myeloma and non-myeloma patients 
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After developing K-M curves and log-rank test of the covariates, we performed univariate and 
multivariate analyses respectively where covariates that had a p<0.25 went in to the multivariate 
model and those with p<0.05 stayed in the multivariate model. 
 
The results of the univariate and multivariate analysis are given in Table 7.   
 
Table 7: Tests of significance of Univariate and Multivariate analysis for myeloma and 
non-myeloma patients using Wald tests 
 
 
Variables  DF P<=0.25 
(Univariate) 
P<=0.05 
(Multivariate) 
Age group 3 <0.001 <0.001 
40-50     
50-60    
60-70    
>70    
Gender 1 0.03 <0.001 
  Female (referent)    
  Male     
Smoking status 1 <0.001 <0.001 
Never(referent)    
Current    
Former    
Diabetes mellitus 1 <0.001 <0.001 
No(referent)    
Yes    
Treatment type 1 <0.001 <0.001 
Haemodialysis (referent)    
Peritoneal dialysis    
Myeloma 1 <0.001 <0.001 
Year of diagnosis of ESKD 2 0.11  
1990-1996 (referent)    
1997-2003    
2004-present    
 
After developing the main effects model, we included interactions terms if p<0.05.  We 
specifically tested only for interactions that seemed plausible with input from Dr Webster, which 
were myeloma with age and sex.  
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Comparison between model with interaction and model without interaction: 
 
The likelihood-ratio test was used to compare the models in terms of fitting data. Clearly, it is 
seen that the interaction of myeloma with sex in model B is not significant (p=0.11). Therefore, 
it will be more logical, if we compare the models that are significant. Accordingly, table 8 shows 
that the Akaike’s Information Criterion (AIC) of model A, which included sex, smoking status, 
treatment type, diabetes and the interaction of myeloma with age, is less than that of the model 
C, the main effect model, which included age, sex, smoking status, treatment type, diabetes and 
myeloma . Therefore, model A, the interaction model, is preferable to model C. The chi-square 
value of this test is 27.12 with p<0.001. That is, model A fits the data better than model C.  
 
 
Table 8: Likelihood-Ratio Test of Models with and without the interaction terms 
 
 
Model Model type Model Elements P-
values 
Log-Log 
(null) 
Log-Log 
(model) 
DF AIC              
C Main effect  Age+sex+smoking 
status+treatment 
type+diabetes+myeloma 
<0.001 -132352.1 -130153.5 9 260324.9   
B Main 
effect+Interaction 
Myeloma×sex 0.11 -132352.1   -130152.2     10 260324.4     
A Main 
effect+Interaction 
Myeloma×age <0.001 -132352.1   -130139.9     12 260303.8 
 
 
 
 
 
 
Model diagnostics: 
 
We performed diagnostic tests based on Schoenfeld for overall and scaled Schoenfeld residuals  
for each covariate to tests whether PH assumption is met. The output of the test is given below: 
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Table 9: Test of proportional hazards assumption 
 
 
 
Variables      Correlation 
coefficient (Rho) 
Chi-squares Degrees of 
freedom  
P-values 
 Age group      
40-50 (referent)     
50-60 0.032 14.27 1 <0.001 
60-70 0.063 57.88 1 <0.001 
>70 0.058 48.12 1 <0.001 
Myeloma by age group      
40-50 (referent) -0.008 0.95 1 0.330 
50-60 0.004 0.27 1 0.606 
60-70 -0.005 0.31 1 0.576 
>70 0.005 0.32 1 0.571 
Sex     
  Female (referent)     
  Male  0.021 6.34 1 0.012 
Smoker      
Never(referent)     
Current 0.019 5.27 1 0.022 
Former -0.008 0.83 1 0.363 
Diabetes      
No(referent)     
Yes -0.004 0.19 1 0.660 
Treatment type     
Haemodialysis (referent)     
Peritoneal dialysis 0.044 27.53 1 <0.001 
Global Test  121.66 12 <0.001 
 
It is seen that the global test is highly significant with p<0.001. Therefore, it is hard to say that 
the overall PH assumption is met. Again, all the covariates met PH assumption except sex, 
treatment type and age group, as their p-values<0.05. As a result, it is recommended that the 
model needs to be stratified by those covariates. However, we will look at the graphical 
representation, an alternative of the statistical test of PH assumption. 
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Figure 9: Log-Log survival curves for PH test 
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Figure 9 shows that all the graphs are almost straight and parallel except age and treatment type, 
where the plot still indicates that PH may not hold as lines crosses. As a result, it is 
recommended that the model needs to be stratified by age and treatment type. 
 
Stratified Cox Model: 
 
The model is built up by stratifying age and treatment type respectively. 
I. Cox Model Stratified by Age: 
 
The output of the Cox model stratified by age group is given in Table 10. 
 
 
Table 10: Age adjusted hazard ratios of death of myeloma and non-myeloma patients  
 
 
Variables Hazard ratio P-values 95% CI 
 
Myeloma by age group   <0.001  
40-50  8.30  (5.66,  12.17) 
50-60 4.57  (3.56,  5.86) 
60-70 3.26  (2.72,  3.92) 
>70 3.10  (2.66,  3.61) 
Sex  <0.001  
  Female (referent)    
  Male  0.92  (0.89, 0.95) 
Smoker   <0.001  
Never(referent)    
Current 1.53  (1.45, 1.62) 
Former 1.19  (1.14, 1.23) 
Diabetes   <0.001  
No(referent)    
Yes 1.38  (1.33, 1.43) 
First treatment type  <0.001  
Haemodialysis (referent)    
Peritoneal dialysis 1.11  (1.07, 1.15) 
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Table 11: Test of proportional hazards assumption after stratifying by Age 
 
 
Variables      Correlation 
coefficient (Rho) 
Chi-squares Degrees of 
freedom  
P-values 
Treatment type     
Haemodialysis (referent)     
Peritoneal dialysis 0.045 28.69 1 <0.001 
 
 
 
 
Figure 10: Log-Log survival curves of treatment type for PH test after stratifying by Age 
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From table 11 and figure 10, it is seen that the treatment type still does not satisfy the 
proportional hazard assumption even after stratifying by age group. Therefore, the model will be 
stratified by age and treatment type. 
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II. Cox Model stratified by age and treatment type: 
 
The output of the Cox model stratified by age and treatment type is given in Table 12. 
Table 12: Age adjusted hazard ratios of death of myeloma and non-myeloma patients  
 
Variables Hazard ratio P-values 95% CI 
 
Myeloma by age group   <0.001  
40-50  8.13  (5.54,  11.93) 
50-60 4.54  (3.54,  5.83) 
60-70 3.19  (2.66,  3.84) 
>70 3.03  (2.60,  3.53) 
Sex  <0.001  
  Female (referent)    
  Male  0.92  (0.89, 0.95) 
Smoker   <0.001  
Never(referent)    
Current 1.53  (1.45, 1.62) 
Former 1.19  (1.15, 1.23) 
Diabetes   <0.001  
No(referent)    
Yes 1.38  (1.33, 1.43) 
 
From table 10 and table 12, it is seen that the hazard ratios of death of myeloma and non-
myeloma patients are almost similar. Therefore, the model stratified by age and the model 
stratified by age and treatment type provide the similar results. As a result, the final model can be 
built up either stratifying by age group only or it can be built up stratifying by both age and 
treatment type. However, if the study needs to estimate the risk of dying between myeloma and 
non-myeloma patients in terms of treatment type, the model needs to be stratified by age group 
only, because the model stratified by treatment type does not provide the estimate of treatment 
type.  
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Figure 11 shows the justification of the Cox model stratified by age: 
 
 
Figure 11: Comparison between Kaplan-Meier survival curves and Cox adjusted survival 
curves 
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We can see that the observed and expected lines are almost matching with each other for the 
respected age group. Therefore, the stratified Cox model is justified using age as a stratification 
variable. 
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Figure 12: Overall goodness of fit of the final model 
 
 
To test whether the model fits the data well, we performed Cox-Snell residual goodness fit test, 
which can be seen as below. If the model fits the data, we would expect the points to lie on the 
45 degrees line. 
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We can see that the points follow the 45 degrees line very closely except for some large values of 
time, which is not a matter of concern for the censored data.  Therefore, we can conclude that the 
graph shows an overall good of fit to the data.  
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Interpretation of results:           
                                                        
 
The hazard ratio of age groups 40-50, 50-60, 60-70 and >70 are 8.30, 4.57, 3.26 and 3.10 
respectively. That is the risk of dying in the myeloma compared to non myeloma group 
decreased with increasing age. Specifically, a patient aged 40-50 years with myeloma is 8.30 
times more likely to die than a similar patient without myeloma. A patient aged 50-60 years with 
myeloma is 4.57 times more likely to die than a similar patient without myeloma. A patient aged 
60-70 years with myeloma is 3.26 times more likely to die than a similar patient without 
myeloma. For patients aged over 70 years, the risk of dying in myeloma patients is 3.10 times 
that of patients without myeloma. The risk of dying is 8% lower in male than that of the female. 
The risk of dying of the patients with myeloma who are currently smoking is 1.53 times that of 
the patients without myeloma who never smoked. Again, the risk of dying of the patients with 
myeloma, who were smoking formerly, is 1.19 times that of the patients without myeloma who 
never smoked. The risk of dying of the patients with myeloma who had diabetes is 1.38 times 
that of the patients without myeloma who did not have diabetes. The result also shows that the 
risk of dying of the patients with myeloma who were treated with peritoneal dialysis is 1.11 
times that of the patients without myeloma who were treated with haemodialysis. It can be 
mentioned here that all the results were highly significant (p<0.001). 
 
 
 
4. Discussion 
 
The results of the analyses presented in the report were consistent with the findings of other 
studies. For example, Leukaemia foundation found that myeloma was more common in men than 
in women (Leukaemia Foundation, 2006). They also found that myeloma was uncommon under 
the age of 60 years. In the ANZDATA registry, we found that myeloma was 62.2% common in 
men and 37.8% in women. We also found that majority (68.4%) of people diagnosed with 
myeloma were over 60 years of age.  
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This report interpreted the results of hazard ratio based on two different models. Model 1 
(Section 3.2) analysed the myeloma patients only and model 2 (Section 3.3) compared the 
myeloma patients with non-myeloma patients on dialysis. In terms of the first analysis (myeloma 
only), only three risk factors were found to be statistically significantly associated with the 
survival of myeloma patients: age, primary renal disease and time of diagnosis of myeloma. The 
risk of dying was higher if the primary kidney disease caused by myeloma compared to other 
diseases. 
 
The second analysis focused on comparing the mortality of myeloma with non-myeloma 
patients.  Specifically, the hazard ratios for myeloma patients were decreasing with increasing 
age when compared with non-myeloma patients, whereas the hazard ratios were increasing with 
increasing age when only the myeloma patients were analysed. Therefore, the risk of dying for 
myeloma patients is increasing with age in absolute terms, but in relative terms the risk of dying, 
although always higher compared to non-myeloma patients, becomes smaller with age.  
 
In terms of the analysis which compared myeloma with non-myeloma dialysis patients, there 
were potentially other approaches that could have been taken, besides restricting the age to 40 
years or older. One option was to analyse the data for all ages. However, we were concerned that 
the results from this approach may have been biased, as myeloma does not occur in children and 
rarely under the age of 40. Another approach might have been to use relative survival. Relative 
survival is the ratio of the observed survival of all causes in the patient group and the expected 
survival of a comparable group from the general population (Simpson and McGeehan, 2008). 
Usually, the general population is the national population, for example, the Australian 
population. However, we wished to compare myeloma with the non-myeloma dialysis patients. 
Hence, in our case the general population would have been the entire dialysis population. This 
approach is worth further investigation but is beyond the scope of this project.   
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Appendix 
 
Table 13: Description of the variables and definitions received from ANZDATA: 
 
Variables Description 
patient ANZDATA patient ID 
disease Primary renal disease 
frsttreatdate Date 1st Renal Replacement Therapy (RRT) treatment 
catype Histological cancer type 
cadate Date cancer diagnosed 
agecancer Age cancer diagnosed 
castage Stage at diagnosis 
sex Gender 
race Ethnicity; white, non-white 
raceother Race others 
firsttxdate First transplant date 
Firstdonor First donor of kidney 
tyedescr Type of cancer description 
causeprd Cause of primary renal disease 
candeath Date of death of cancer 
causedeath Cause of death of cancer 
smoker Smoker at 1st RRT 
diabetes Diabetes Mellitus 
diabdate Date of diabetes 
45 
 
initstat State resident at 1st RRT 
statedia State resident at cancer diagnosis 
primsite Cancer site code 
last Last known outcome 
datdeath Date of last known outcome 
initstat State resident at 1st RRT 
statedia State resident at cancer diagnosis 
status Death or alive 
era Year of 1st transplant 
fuptime Duration from Tx to last known 
prd Primary cause of ESRF 
Agetxcat Age categorisation around age at tx quartiles, for those 
with cancer 'events' 
rrttime Duration RRT prior to 1st tx 
cancer cancer ever, no CIN (cervical cancer) 
firsttreat 1st treatment code 
sequ Patient sequence 
sequtot Patient max sequence 
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Table 14: Description of the variables and definitions derived and defined 
after receiving ANZDATA: 
New/Re-categorisation of  
variables 
Description 
firsttreat_type Categorisation of 1st treatment separating dialysis and 
transplant patients 
firstdxdate First treatment date dialysis only 
myeloma Separating myeloma cancer using cancer type=10 
mycadate Myeloma cancer date 
myeloma_ever Separating myeloma and non-myeloma patients 
timebetn Generating time between getting myeloma & other cancer  
eskd_between Time between myeloma and End Stage Kidney 
Disease(ESKD) 
fuptime Duration from dialysis to last known 
status Dead(1) and alive or temp recovery or lost(0) 
prd Categorisation of primary cause of ESKD 
era Year of 1st dialysis 
agedx Age at 1st dialysis 
agedxcat Categorisation of age at 1st dialysis 
myelomaeskd Duration of Myeloma diagnosis 
era_eskd Year of ESKD date 
era_eskdgp Categorisation of era_eskd 
era_myeloma Year of Myeloma cancer date 
era_myelomagp Categorisation of era_myeloma 
pkd Re-categorisation of prd into smaller group 
 
